Whittier Trust Co. of Nevada Inc. maintained its position in Chemed Corp. (NYSE:CHE) during the second quarter, according to its most recent filing with the SEC. The firm owned 500 shares of the company’s stock at the end of the second quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Chemed Corp. were worth $102,000 as of its most recent filing with the SEC.
Several other institutional investors have also added to or reduced their stakes in the stock. Norges Bank acquired a new position in Chemed Corp. during the fourth quarter valued at approximately $38,052,000. Teachers Advisors LLC boosted its position in Chemed Corp. by 2.6% in the fourth quarter. Teachers Advisors LLC now owns 29,537 shares of the company’s stock valued at $4,738,000 after buying an additional 744 shares during the period. Private Trust Co. NA acquired a new position in Chemed Corp. during the first quarter valued at approximately $455,000. Parametrica Management Ltd acquired a new position in Chemed Corp. during the first quarter valued at approximately $352,000. Finally, Louisiana State Employees Retirement System boosted its position in Chemed Corp. by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 6,600 shares of the company’s stock valued at $1,206,000 after buying an additional 100 shares during the period. Institutional investors own 97.78% of the company’s stock.
Shares of Chemed Corp. (NYSE CHE) traded up 0.06% during trading on Friday, reaching $187.59. The company had a trading volume of 75,906 shares. Chemed Corp. has a 12 month low of $130.05 and a 12 month high of $216.01. The firm has a market capitalization of $3.00 billion, a PE ratio of 46.54 and a beta of 1.14. The stock has a 50 day moving average price of $199.37 and a 200 day moving average price of $192.75.
Chemed Corp. (NYSE:CHE) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.89 by $0.26. The business had revenue of $415.06 million for the quarter, compared to analyst estimates of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. Chemed Corp.’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.80 EPS. On average, equities research analysts forecast that Chemed Corp. will post $8.20 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Monday, August 14th will be paid a $0.28 dividend. This is a positive change from Chemed Corp.’s previous quarterly dividend of $0.26. The ex-dividend date of this dividend is Thursday, August 10th. This represents a $1.12 annualized dividend and a yield of 0.60%. Chemed Corp.’s payout ratio is currently 28.07%.
ILLEGAL ACTIVITY NOTICE: This piece was reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/whittier-trust-co-of-nevada-inc-has-102000-stake-in-chemed-corp-che-updated-updated-updated.html.
Several equities analysts have recently commented on CHE shares. Zacks Investment Research cut Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. BidaskClub cut Chemed Corp. from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 22nd. Royal Bank Of Canada reiterated a “hold” rating and set a $208.00 target price on shares of Chemed Corp. in a research note on Wednesday, July 5th. TheStreet cut Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Finally, Oppenheimer Holdings, Inc. raised their price objective on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research note on Thursday, July 27th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $218.33.
In related news, insider Kevin J. Mcnamara sold 15,000 shares of the business’s stock in a transaction on Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the sale, the insider now owns 173,801 shares of the company’s stock, valued at approximately $34,961,809.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director George J. Walsh III purchased 1,000 shares of the firm’s stock in a transaction that occurred on Monday, June 26th. The stock was bought at an average cost of $204.56 per share, for a total transaction of $204,560.00. Following the purchase, the director now owns 7,908 shares in the company, valued at $1,617,660.48. The disclosure for this purchase can be found here. 5.32% of the stock is owned by insiders.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.